Goldman Sachs
ITCI

Goldman Sachs’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Goldman Sachs’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-10,000
Closed -$130K – 5423
2019
Q2 		$130K Buy
+10,000
New +$128K ﹤0.01% 4884

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Goldman Sachs's ITCI Position: Q2 2025 in Review

Goldman Sachs sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 1,473,764 shares — an estimated $194M sold.

Goldman Sachs first reported a position in ITCI in Q2 2014 and held it in 43 quarters. The position peaked at $194M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Goldman Sachs reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Goldman Sachs sold 1,473,764 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $194M.
  • Goldman Sachs first reported a position in Intra-Cellular Therapies Inc. in Q2 2014 and held it in 43 quarters.
  • Goldman Sachs's Intra-Cellular Therapies Inc. position peaked at $194M in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Goldman Sachs's 13F filing for Q2 2025, filed 14 Aug 2025.